I-spy trials: quantum leap sponsors the i-spy trials (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis). I-spy has been re-engineering the approach to clinical trials, with a goal of getting the right drug to the right patient at the time when they will benefit most, and to achieve this faster than possible in previous trial models. Additionally, i-spy aims to significantly reduce the overall cost, time, and number of patients required to bring new drugs to market. The i-spy trial program integrates and links phase i (i-spy phase 1), phase II (i-spy 2), and future phases to build a pipeline of novel agents and accelerate the process of identifying the subset of high-risk breast cancer patients that will benefit from these new agents, and get these drug into the clinic in a timely manner.

Breast cancer trails (bct) - launched in 2008, following a successful ucsf-nci sponsored research pilot, its mission is to make patient consideration of trials the norm vs. The exception. We believe that all patients should have access to the latest medical knowledge about breast cancer treatment as well as the opportunity to advance breast cancer research. Bct lists over 600 studies for people with newly diagnosed breast cancer, metastatic disease, or post-treatment survivors. It includes innovative trials of targeted and immunotherapies as well as observational studies looking at quality of life, genetic mutations, and breast cancer survivorship, accompanied by easy-to-read trial summaries.

Collaboration with the athena breast health network - the athena breast health network ("athena") is a collaboration of the five university of california medical centers and sanford health to drive innovation in breast cancer prevention, screening and treatment. A large-scale demonstration project, athena integrates clinical care and research to drive innovation in prevention, screening, treatment and management of breast cancer. This project will improve survival and reduce suffering from breast cancer by accelerating the time between research discoveries and innovative patient treatments. Major initiatives include risk assessment and evaluation, radiology harmonization, pathology harmonization, and improving survivorship care.